NEW YORK, Nov. 9 /PRNewswire/ -- Research advances in molecular diagnostics, imaging, and nanotechnology, and their impact on drug development will be presented by a faculty of 20+ leading researchers at an industry forum geared towards networking and discussion, announces Strategic Research Institute. Genomic, proteomic, and metabolite markers, pharmacogenomic applications, in vivo imaging, and nanotechnology will be addressed, along with their translation into current efforts in optimizing diagnosis and therapeutic development. Presenters include: Pfizer, Eli Lilly, Bristol Myers Squibb, Bayer Diagnostics, Celera Diagnostics, Quest Diagnostics, Epix Pharmaceuticals, National Cancer Institute, National Center for Genome Resources, Philips Medical Systems, Kereos, Cepheid, Metabolon, Abbott Laboratories, and many others. The meeting, scheduled for February, 2005, is designed to provide an open forum for discussion and audience participation via interactive roundtable discussions and workshops on commercialization, regulation, and imaging technologies. Agenda, registration, and detailed information is available at http://www.srinstitute.com/cs327 To request announcement, group discount information, or for speaking opportunities, please contact Steve J. Kuperberg at firstname.lastname@example.org or call 212 967-0095 x261.
SOURCE Strategic Research Institute